Association of homocysteine with type 2 diabetes: A meta-analysis implementing Mendelian randomization approach

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Huang, Tao ^a,b,c   Ren, JingJing ^d   Huang, Jinyan ^e   Li, Duo ^b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c APCNS Centre of Nutrition and Food Safety   (China)

^d ZHEJIANG UNIVERSITY   (China)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Homocysteine; MTHFR; Type 2 diabetes

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; CAUSAL ATTRIBUTION; CONTROLLED STUDY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MENDELIAN RANDOMIZATION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT;

ALLELES; DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); RISK FACTORS;

EID: 84889824353     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-867     Document Type: Article

References (67)

1. King GL, Kunisaki M, Nishio Y, Inoguchi T, Shiba T, et al. Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes 1996, 45:S105-S108.
2. Hoogeveen EK, Kostense PJ, Beks PJ, MacKaay AJC, Jakobs C, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus - a population-based. Arterioscler Thromb Vasc Biol 1998, 18:133-138. 10.1161/01.ATV.18.1.133, 9445267.
3. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome - the Framingham offspring study. Diabetes Care 2001, 24:1403-1410. 10.2337/diacare.24.8.1403, 11473077.
4. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000, 23:1816-1822. 10.2337/diacare.23.12.1816, 11128359.
5. Kark JD, Selhub J, Bostom A, Adler B, Rosenberg IH. Plasma homocysteine and all-cause mortality in diabetes. Lancet 1999, 353:1936-1937.
6. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes - 5-year follow-up of the Hoorn study. Circulation 2000, 101:1506-1511. 10.1161/01.CIR.101.13.1506, 10747342.
7. Agullo-Ortuno MT, Albaladejo MD, Parra S, Rodriguez-Manotas M, Fenollar M, et al. Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin Chim Acta 2002, 326:105-112. 10.1016/S0009-8981(02)00287-5, 12417101.
8. Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, et al. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 2001, 24:533-538. 10.2337/diacare.24.3.533, 11289481.
9. Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, et al. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999, 22:125-132. 10.2337/diacare.22.1.125, 10333913.
10. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993, 103:149-157. 10.1016/0021-9150(93)90258-V, 8292092.
11. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998, 98:204-210. 10.1161/01.CIR.98.3.204, 9697819.
12. Mazza A, Bossone E, Mazza F, Distante A. Reduced serum homocysteine levels in type 2 diabetes. Nutr Metab Cardiovasc Dis 2005, 15:118-124. 10.1016/j.numecd.2004.03.001, 15871860.
13. Oishi K, Nagake Y, Yamasaki H, Fukuda S, Ichikawa H, et al. The significance of serum homocysteine levels in diabetic patients on haemodialysis. Nephrol Dial Transplant 2000, 15:851-855. 10.1093/ndt/15.6.851, 10831640.
14. Lander ES. The new genomics: global views of biology. Science 1996, 274:536-539. 10.1126/science.274.5287.536, 8928008.
15. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93:7-9. 10.1161/01.CIR.93.1.7, 8616944.
16. Zintzaras E, Chatzoulis DZ, Karabatsas CH, Stefanidis I. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. J Hum Genet 2005, 50:267-275. 10.1007/s10038-005-0250-z, 15902512.
17. Hemati T, Moghadami-Tabrizi N, Davari-Tanha F, Salmanian B, Javadian P. High plasma homocysteine and insulin resistance in patients with polycystic ovarian syndrome. Iranian Journal of Reproductive Medicine 2011, 9:223-228.
18. Nafiye Y, Sevtap K, Muammer D, Emre O, Senol K, et al. The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. Fertil Steril 2010, 93:1864-1869. 10.1016/j.fertnstert.2008.12.024, 19171332.
19. Malek-Khosravi S, Kaboudi M, Kaboudi B, Atefi G. Plasma homocysteine concentrations and insulin resistance in preeclampsia. Hypertens Pregnancy 2009, 28:13-22. 10.1080/10641950802233049, 19165666.
20. Patterson S, Flatt PR, Brennan L, Newsholme P, McClenaghan NH. Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic beta-cell glucose metabolism and insulin secretion. J Endocrinol 2006, 189:301-310. 10.1677/joe.1.06537, 16648297.
21. Patterson S, Flatt PR, McClenaghan NH. Homocysteine-induced impairment of insulin secretion from clonal pancreatic BRIN-BD11 beta-cells is not prevented by catalase. Pancreas 2007, 34:144-151. 10.1097/01.mpa.0000240613.43345.51, 17198197.
22. Scullion SMJ, Gurgul-Convey E, Elsner M, Lenzen S, Flatt PR, et al. Enhancement of homocysteine toxicity to insulin-secreting BRIN-BD11 cells in combination with alloxan. J Endocrinol 2012, 214:233-238. 10.1530/JOE-11-0461, 22582095.
23. Russo GT, Di Benedetto A, Magazzù D, Giandalia A, Giorda CB, et al. Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductasegene and the risk of macroangiopathy in type 2 diabetes: a prospective study. Acta Diabetol 2011, 48:95-101. 10.1007/s00592-009-0169-5, 19937354.
24. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, et al. Homocysteine, MTHFR 677CT polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002, 59:529-536. 10.1212/WNL.59.4.529, 12196644.
25. Ndrepepa G, Kastrati A, Braun S, Koch W, Kolling K, et al. Circulating homocysteine levels in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2008, 18:66-73. 10.1016/j.numecd.2006.03.007, 17027242.
26. Bluthner M, Bruntgens A, Schmidt S, Strojek K, Grzeszczak W, et al. Association of methylenetetrahydrofolate reductase gene polymorphism and diabetic nephropathy in type 2 diabetes?. Nephrol Dial Transplant 1999, 14:56-57. 10.1093/ndt/14.1.56, 10052477.
27. Benes P, Kankova K, Muzik J, Groch L, Benedik J, et al. Methylenetetrahydrofolate reductase polymorphism, type II diabetes mellitus, coronary artery disease, and essential hypertension in the Czech population. Mol Genet Metab 2001, 73:188-195. 10.1006/mgme.2001.3188, 11386855.
28. Yilmaz H, Agachan B, Ergen A, Karaalib ZE, Isbir T. Methylene tetrahydrofolate reductase C677T mutation and left ventricular hypertrophy in Turkish patients with type II diabetes mellitus. J Biochem Mol Biol 2004, 37:234-238. 10.5483/BMBRep.2004.37.2.234, 15469701.
29. Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, et al. The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract 2007, 78:355-359. 10.1016/j.diabres.2007.06.005, 17681394.
30. Tutuncu NB, Erbas T, Alikasifoglu M, Tuncbilek E. Thermolabile methylenetetrahydrofolate reductase enzyme genotype is frequent in type 2 diabetic patients with normal fasting homocysteine levels. J Intern Med 2005, 257:446-453. 10.1111/j.1365-2796.2005.01480.x, 15836661.
31. Soares AL, Fernandes AP, Cardoso JE, Sousa MO, Lasmar MC, et al. Plasma total homocysteine levels and methylenetetrahydrofolate reductase gene polymorphism in patients with type 2 diabetes mellitus. Pathophysiol Haemost Thromb 2007, 36:275-281.
32. Angeline T, Thiruvarutselvi G, Isabel W, Aruna RM, Devi R, et al. MTHFR (Ala 222 Val) polymorphism and AMI in patients with type II diabetes mellitus. Indian J Clin Biochem 2009, 24:137-141. 10.1007/s12291-009-0025-y, 3453219, 23105822.
33. Mehri S, Koubaa N, Nakbi A, Hammami S, Chaaba R, et al. Relationship between genetic polymorphisms of angiotensin-converting enzyme and methylenetetrahydrofolate reductase as risk factors for type 2 diabetes in Tunisian patients. Clin Biochem 2010, 43:259-266. 10.1016/j.clinbiochem.2009.10.008, 19857476.
34. Sun JH, Xu YC, Zhu YL, Lu HY. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract 2004, 64:185-190. 10.1016/j.diabres.2003.10.022, 15126006.
35. Mtiraoui N, Ezzidi I, Chaieb M, Marmouche H, Aouni Z, et al. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract 2007, 75:99-106. 10.1016/j.diabres.2006.05.018, 16828193.
36. Sun J, Xu Y, Zhu Y, Lu H, Deng H, et al. The relationship of methylenetetrahydrofolate reductase gene polymorphism and plasma homocysteine levels in type 2 diabetes mellitus patients with diabetic retinopathy. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003, 20:131-134.
37. Movva S, Alluri RV, Venkatasubramanian S, Vedicherla B, Vattam KK, et al. Association of methylene tetrahydrofolate reductase C677T genotype with type 2 diabetes mellitus patients with and without renal complications. Genet Test Mol Biomarkers 2011, 15:257-261. 10.1089/gtmb.2010.0118, 21186995.
38. Bazzaz JT, Shojapoor M, Nazem H, Amiri P, Fakhrzadeh H, et al. Methylenetetrahydrofolate reductase gene polymorphism in diabetes and obesity. Mol Biol Rep 2010, 37:105-109. 10.1007/s11033-009-9545-z, 19437140.
39. Benrahma H, Abidi O, Melouk L, Ajjemami M, Rouba H, et al. Association of the C677T Polymorphism in the Human Methylenetetrahydrofolate Reductase (MTHFR) gene with the genetic predisposition for Type 2 diabetes mellitus in a Moroccan Population. Genet Test Mol Biomarkers 2012, 16:383-387. 10.1089/gtmb.2011.0179, 22103601.
40. Sharaf SM, Gawish HH, Elsherbiny EM. Methylenetetrahydrofolate Reductase (Mthfr C677t) Gene Polymorphism Effect on Development of Diabetic Nephropathy in Egyptien Patients with Type 2 Diabetes Mellitus. Life Science Journal-Acta Zhengzhou University Overseas Edition 2012, 9:874-880.
41. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558. 10.1002/sim.1186, 12111919.
42. Song YQ, Yeung E, Liu AY, VanderWeele TJ, Chen LW, et al. Pancreatic beta-cell function and type 2 diabetes risk: quantify the causal effect using a Mendelian randomization approach based on meta-analyses. Hum Mol Genet 2012, 21:5010-5018. 10.1093/hmg/dds339, 3607483, 22936689.
43. Glymour MM, Tchetgen EJT, Robins JM. Credible mendelian randomization studies: approaches for evaluating the instrumental variable assumptions. Am J Epidemiol 2012, 175:332-339. 10.1093/aje/kwr323, 3366596, 22247045.
44. Tanaka T, Scheet P, Giusti B, Bandinelli S, Piras MG, et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet 2009, 84:477-482. 10.1016/j.ajhg.2009.02.011, 2667971, 19303062.
45. Huang T, Tucker KL, Lee YC, Crott JW, Parnell LD, et al. Methylenetetrahydrofolate reductase variants associated with hypertension and cardiovascular disease interact with dietary polyunsaturated fatty acids to modulate plasma homocysteine in puerto rican adults. J Nutr 2011, 141:654-659. 10.3945/jn.110.134353, 3056580, 21270364.
46. Thompson JR, Minelli C, Abrams KR, Tobin MD, Riley RD. Meta-analysis of genetic studies using Mendelian randomization - a multivariate approach. Stat Med 2005, 24:2241-2254. 10.1002/sim.2100, 15887296.
47. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002, 325:1202-1206K.
48. Mazza A, Motti C, Nulli A, Pastore A, Andreotti F, et al. Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects. J Thromb Thrombolysis 1999, 8:207-212. 10.1023/A:1008962220476, 10500310.
49. Hermans MP, Gala JL, Buysschaert M. The MTHFR C677T polymorphism confers a high risk for stroke in both homozygous and heterozygous T allele carriers with Type 2 diabetes. Diabet Med 2006, 23:529-536. 10.1111/j.1464-5491.2006.01841.x, 16681562.
50. Scaglione L, Gambino R, Rolfo E, Lillaz E, Gai M, et al. Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest 2002, 32:24-28.
51. Ozmen B, Ozmen D, Turgan N, Habif S, Mutaf I, et al. Association between homocysteinemia and renal function in patients with type 2 diabetes mellitus. Ann Clin Lab Sci 2002, 32:279-286.
52. Tessari P, Coracina A, Kiwanuka E, Vedovato M, Vettore M, et al. Effects of insulin on methionine and homocysteine kinetics in type 2 diabetes with nephropathy. Diabetes 2005, 54:2968-2976. 10.2337/diabetes.54.10.2968, 16186400.
53. Helfenstein T, Fonseca FAH, Relvas WGM, Santos AO, Dabela ML, et al. Prevalence of myocardial infarction is related to hyperhomocysteinemia but not influenced by C677T methylenetetrahydrofolate reductase and A2756G methionine synthase polymorphisms in diabetic and non-diabetic subjects. Clin Chim Acta 2005, 355:165-172. 10.1016/j.cccn.2004.12.002, 15820491.
54. Koubaa N, Nakbi A, Smaoui A, Abid N, Chaaba R, et al. yperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clin Biochem 2007, 40:1007-1014. 10.1016/j.clinbiochem.2007.05.017, 17618615.
55. Ratnam S, Maclean KN, Jacobs RL, Brosnan ME, Kraus JP, et al. Hormonal regulation of cystathionine beta-synthase expression in liver. J Biol Chem 2002, 277:42912-42918. 10.1074/jbc.M206588200, 12198128.
56. Dicker-Brown A, Fonseca VA, Fink LA, Kern PA. The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes. Atherosclerosis 2001, 158:297-301. 10.1016/S0021-9150(01)00442-7, 11583707.
57. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996, 58:35-41. 1914961, 8554066.
58. Moczulski D, Fojcik H, Zukowska-Szczechowska E, Szydlowska I, Grzeszczak W. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 2003, 18:1535-1540. 10.1093/ndt/gfg211, 12897091.
59. Chango A, Potier De Courcy G, Boisson F, Guilland JC, Barbe F, et al. 5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) cohort. Br J Nutr 2000, 84:891-896.
60. Kluijtmans LA, Young IS, Boreham CA, Murray L, McMaster D, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003, 101:2483-2488. 10.1182/blood.V101.7.2483, 12642343.
61. Brown KS, Kluijtmans LA, Young IS, Murray L, McMaster D, et al. The 5,10-methylenetetrahydrofolate reductase C677T polymorphism interacts with smoking to increase homocysteine. Atherosclerosis 2004, 174:315-322. 10.1016/j.atherosclerosis.2004.01.023, 15136061.
62. Maeda M, Yamamoto I, Fukuda M, Nishida M, Fujitsu J, et al. MTHFR gene polymorphism as a risk factor for diabetic retinopathy in type 2 diabetic patients without serum creatinine elevation. Diabetes Care 2003, 26:547-548.
63. Ksiazek P, Bednarek-Skublewska A, Buraczynska M. The C677T methylenetetrahydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus. Med Sci Monit 2004, 10:BR47-51.
64. Ioannidis JPA, Ntzani EE, Trikalinos TA. 'Racial' differences in genetic effects for complex diseases. Nat Genet 2004, 36:1312-1318. 10.1038/ng1474, 15543147.
65. Ioannidis JPA, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003, 361:567-571. 10.1016/S0140-6736(03)12516-0, 12598142.
66. Pfeiffer CM, Huff DL, Smith SJ, Miller DT, Gunter EW. Comparison of plasma total homocysteine measurements in 14 laboratories: an international study. Clin Chem 1999, 45:1261-1268.
67. Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE. Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes 2009, 58(8):1921-8. 10.2337/db09-0087, 2712772, 19491213.